HTRS Hosts Webinar: Novel Therapies In VWD And Rare Bleeding Disorders
Hemostasis & Thrombosis Research Society (HTRS) posted on LinkedIn:
”Join HTRS for our upcoming educational webinar: “Novel Therapies in VWD and Rare Bleeding Disorders” on Tuesday, October 21 at 3:00PM EST.
Discover the latest advances in treatment and research for von Willebrand disease (VWD) and rare bleeding disorders with two renowned experts:
Dr. Debbie Jiang – Adult classical hematologist at Massachusetts General Hospital and the Boston Bleeding Disorders Center. A recipient of the HTRS/Novo Nordisk Clinical Scholar Award, Dr. Jiang is dedicated to advancing care and research for bleeding and clotting disorders.
Dr. Stacy Croteau – Pediatric hematologist and clinical researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. As Medical Director of the Boston Bleeding Disorders Center and National Chair of the ATHN/NHPCC Transition Working Group, Dr. Croteau leads efforts to improve outcomes and transitions of care for individuals with bleeding disorders.
Don’t miss this opportunity to hear directly from leaders shaping the future of bleeding disorder care. Register now to secure your spot.”
Stay updated with Hemostasis Today.
-
Apr 30, 2026, 18:19Deva Nanda TK: A Practical Overview of Dural Sinuses and The Venous Drainage of the Brain
-
Apr 30, 2026, 18:08Amrit Kaur Kaler: The Hidden Genetic Drivers of Thrombosis
-
Apr 30, 2026, 18:06Alejandro González Veliz: The Most Dangerous Mistake After Getting a Stent
-
Apr 30, 2026, 18:03Carmen Ruiz: First Arterial Mechanical Thrombectomy in New Zealand Using the ARTIX System
-
Apr 30, 2026, 17:52Simon Senanu: von Willebrand Disease May Be Missed Despite Normal Tests
-
Apr 30, 2026, 17:20José Antonio García Erce: Why Healthy Older Adults Should Keep Donating Blood?
-
Apr 30, 2026, 17:13Paul Logan: Decoding the Words ‘He’s on blood thinners’
-
Apr 30, 2026, 17:01Jason Andrade: A Decade-Long Quest Proves Early Ablation Halves Persistent AF Burden
-
Apr 30, 2026, 16:56Oliver Maracic: Could Co-Targeting ALK with FAK/PYK2 Help Mitigate the High VTE Burden Seen in ALK with NSCLC